[
  {
    "ts": null,
    "headline": "Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study",
    "summary": "Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate response to standard therapies. The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks compared to placebo. In the Phase 3b APEX st",
    "url": "https://finnhub.io/api/news?id=9756afccad576fc1bfcb5910d2497e3a27cd42db0cd2b38571531b7ccb284e42",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743791730,
      "headline": "Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study",
      "id": 133727281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate response to standard therapies. The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks compared to placebo. In the Phase 3b APEX st",
      "url": "https://finnhub.io/api/news?id=9756afccad576fc1bfcb5910d2497e3a27cd42db0cd2b38571531b7ccb284e42"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
    "summary": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
    "url": "https://finnhub.io/api/news?id=ae246bbde822dc8bf43585c2f475d490ec308d940338bb60f74d2d50bd966320",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743771840,
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
      "id": 133719365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
      "url": "https://finnhub.io/api/news?id=ae246bbde822dc8bf43585c2f475d490ec308d940338bb60f74d2d50bd966320"
    }
  },
  {
    "ts": null,
    "headline": "1 Ideal Buy From 23 \"Safer\" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)",
    "summary": "Discover top investment opportunities: Fortune 50 highlights admired companies with strong dividends. Read the full list of stock picks here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=32d998c2fae31ad28c34ec6e39c3013ff821c16b7608d3c185838636ef8c20c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743771672,
      "headline": "1 Ideal Buy From 23 \"Safer\" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)",
      "id": 133719190,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172736149/image_172736149.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover top investment opportunities: Fortune 50 highlights admired companies with strong dividends. Read the full list of stock picks here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=32d998c2fae31ad28c34ec6e39c3013ff821c16b7608d3c185838636ef8c20c7"
    }
  },
  {
    "ts": null,
    "headline": "TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1",
    "url": "https://finnhub.io/api/news?id=591b464416746009a30079dc6d65477f1ae2b357040db7b5929ed3507e8f3033",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743768300,
      "headline": "TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis",
      "id": 133704623,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1",
      "url": "https://finnhub.io/api/news?id=591b464416746009a30079dc6d65477f1ae2b357040db7b5929ed3507e8f3033"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Global Survey Reveals Confidence in AI and Medical Technology to Address Personalized Needs of the Aging Population and Alleviate Burnout Among Healthcare Professionals",
    "summary": "New Brunswick, NJ. - With the global population over 60 expected to double by 2050, the healthcare industry faces significant challenges, increasing the need for specialized care for age-related...",
    "url": "https://finnhub.io/api/news?id=4f47268a25763dd137fca74782d4cd529f9d780ea6d94f15f64bd7c088744ed9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743765692,
      "headline": "Johnson & Johnson Global Survey Reveals Confidence in AI and Medical Technology to Address Personalized Needs of the Aging Population and Alleviate Burnout Among Healthcare Professionals",
      "id": 133711466,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "New Brunswick, NJ. - With the global population over 60 expected to double by 2050, the healthcare industry faces significant challenges, increasing the need for specialized care for age-related...",
      "url": "https://finnhub.io/api/news?id=4f47268a25763dd137fca74782d4cd529f9d780ea6d94f15f64bd7c088744ed9"
    }
  },
  {
    "ts": null,
    "headline": "Nanobiotix SA (NBTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges",
    "summary": "Despite a significant net loss, Nanobiotix SA (NBTX) extends its cash runway and strengthens its partnership with Johnson & Johnson.",
    "url": "https://finnhub.io/api/news?id=92305d924239b9e03779e0dd93437d580b8952aa9bf3a8a504af7fe46dba722d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743750028,
      "headline": "Nanobiotix SA (NBTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges",
      "id": 133704626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Despite a significant net loss, Nanobiotix SA (NBTX) extends its cash runway and strengthens its partnership with Johnson & Johnson.",
      "url": "https://finnhub.io/api/news?id=92305d924239b9e03779e0dd93437d580b8952aa9bf3a8a504af7fe46dba722d"
    }
  }
]